Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)
Primary Purpose
22q13 Deletion Syndrome, Phelan-McDermid Syndrome
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Insulin-Like Growth Factor-1 (IGF-1)
Normal saline
Sponsored by
About this trial
This is an interventional treatment trial for 22q13 Deletion Syndrome focused on measuring SHANK3, IGF-1, Autism
Eligibility Criteria
Inclusion Criteria:
- 5 to 12 years old
- pathogenic deletions or mutations of the SHANK3 gene
- stable medication regimens for at least three months prior to enrollment
Exclusion Criteria:
- closed epiphyses
- active or suspected neoplasia
- intracranial hypertension
- hepatic insufficiency
- renal insufficiency
- cardiomegaly / valvulopathy
- history of allergy to IGF-1 or any component of the formulation (mecasermin)
- history of extreme prematurity (<1000 grams) with associated early neo-natal complications, e.g. intra-cerebral hemorrhage, prolonged hypoxia, prolonged hypoglycemia
- patients with comorbid conditions deemed too medically compromised to tolerate the risk of experimental treatment with IGF-1
Sites / Locations
- Seaver Austin Center, Icahn School of Medicine at Mount Sinai
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Insulin-Like Growth Factor-1 (IGF-1)
Normal saline
Arm Description
Injection
Injection
Outcomes
Primary Outcome Measures
Change in Aberrant Behavior Checklist - Social Withdrawal (ABC-SW) Subscale - Study 1
16 items on ABC-SW subscale, Each item is scored as 0 (never a problem), 1 (slight problem), 2 (moderately serious problem), or 3 (severe problem). Total score from 0 to 48 with higher score indicating poorer health outcomes.
Change in Aberrant Behavior Checklist - Social Withdrawal (ABC-SW) Subscale Study 2
16 items on ABC-SW subscale, Each item is scored as 0 (never a problem), 1 (slight problem), 2 (moderately serious problem), or 3 (severe problem). Total score from 0 to 48 with higher score indicating poorer health outcomes..
Secondary Outcome Measures
Change in Repetitive Behavior Scale - Study 2
Repetitive Behavior Scale (RBS) - Total Score 43 items, each item scored on 4-point scale: 0-Behavior does not occur, 1-Behavior occurs and is a mild problem, 2-Behavior occurs and is a moderate problem, 3-Behavior occurs and is a severe problem. with total score from 0 (mild) to 129 (severe).
The subscales are stereotyped behaviors 6 items (subscale 0-18), self-injurious behaviors 8 items (subscale 0-24), Compulsive behaviors- 8 items (subscale 0-24), Ritualistic Behaviors 6 items (subscale from 0-18), Sameness 11 items (subscale 0-33), restricted behaviors 4 items (subscale 0-12). Total score is the sum of all items in the subscale with total score range from 0 to 129. Higher scores indicate greater symptom severity.
Change in CGI-Improvement and Severity Scales; - Study 2
The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.
The Clinical Global Impression - Improvement scale (CGI-I) is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. and rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.
Change in Caregiver Strain Questionnaire
21 question tool, about caregiver strain, where each question uses a Likert scale where 1 is "Not at all" and 5 is "Very much." The full scale ranges from 21-105, where higher scores indicate more severe strain.
Change in Sensory Profile (SP) - Study 2
The SP is a standardized parent-completed questionnaire that assesses sensory processing and its impact on the functioning of children ages 3-10 yr. The 125 items represent behaviors that can be interpreted as responses to sensory experiences. The parent rates the observed frequency of these behaviors on a 5-point Likert scale (ranging from 1 always to 5 never). The tool consists of 14 sections, listed below, that refer to sensory processing, modulation, and behavioral and emotional responses. Subscale scores are listed below.
Each section's raw score is compared with a threshold value to determine a category of performance: typical performance, probable difference (1 standard deviation below the mean), and definite difference (2 standard deviations below the mean). A lower raw score means a greater difference.
Change in Short Sensory Profile (SSP) - Study 2
The Short Sensory Profile is a caregiver report measure consisting of 38 items, each scored on a 1-point (always) to 5-point (never) Likert scale.
SSP Subscales Tactile Sensitivity (7 to 35) Taste/Smell Sensitivity (4 to 20), Movement Sensitivity (3 to 15), Under-Responsive/Seek Sensation (7 to 35) , Auditory Filtering (6 to 30), Low Energy/Weak (6 to 30), Visual/Auditory Sensitivity (5 to 25), with total scale from (38 to 190)
Lower scores indicate more sensory alterations.
Full Information
NCT ID
NCT01525901
First Posted
February 1, 2012
Last Updated
April 18, 2022
Sponsor
Icahn School of Medicine at Mount Sinai
Collaborators
National Institute of Mental Health (NIMH)
1. Study Identification
Unique Protocol Identification Number
NCT01525901
Brief Title
Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)
Official Title
A Double-Blind Placebo-Controlled Crossover Trial of Insulin-Like Growth Factor-1 (IGF-1) in Children and Adolescents With 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)
Study Type
Interventional
2. Study Status
Record Verification Date
April 2022
Overall Recruitment Status
Completed
Study Start Date
February 2012 (undefined)
Primary Completion Date
August 23, 2016 (Actual)
Study Completion Date
August 23, 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Icahn School of Medicine at Mount Sinai
Collaborators
National Institute of Mental Health (NIMH)
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to pilot the use of Insulin-Like Growth Factor-1 (IGF-1) treatment in 22q13 Deletion Syndrome (Phelan-McDermid Syndrome) caused by SHANK3 gene deficiency in order to evaluate safety, tolerability, and efficacy. IGF-1 is an injection under the skin that contains human IGF-1. IGF-1 is approved by the FDA under the brand name Increlex for the treatment of children with short stature due to primary IGF-1 deficiency. It is being used off-label in the current study and is not FDA approved, nor has it yet been studied in humans for the treatment of SHANK3 deficiency.
Detailed Description
Overall, there will be 1-3 screening visits, a baseline visit where study drug will first be administered, and then 10 follow-up visits. Follow-up visits will occur at week 2, week 4, week 8, and week 12 in each treatment phase (IGF-1 or placebo), and then again 4 weeks after study completion, Parents/guardians will be asked to administer the IGF-1/ placebo by injection at home and will also be responsible for monitoring glucose levels in the child. Parents/guardians will be trained in these methods, and will have scheduled phone calls and appointments where the dose and tolerability will be discussed.
Assessments include the following:
Physical and neurological examination
Medical and psychiatric history
X-ray of long bone (e.g., hand) to ensure your child's growth plates are not closed
Electrocardiography
Echocardiography
Pregnancy test if applicable
Lab safety measures (through blood draw)
Autism Diagnostic Interview (ADI)
Autism Diagnostic Observation Schedule (ADOS)
The Mullen Scales of Early Learning or the Leiter International Performance Scale-Revised
Vineland Adaptive Behavior Scale (VABS)
Clinical Global Impressions (CGI) Rating Scales
The Repetitive Behaviors Scale (RBS)
Aberrant Behavior Checklist (ABC)
The Caregiver Strain Questionnaire (CSI)
Language Environment Analysis (LENA)
The Macarthur-Bates Communication Inventory (MCDI)
Unified Parkinson's Disease Rating Scale (UPDRS)
Quick Neurological Screening Test 2nd Edition (QNST-2)
Gait Analysis with motion capture video systems and interactive 3-dimensional modeling systems
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
22q13 Deletion Syndrome, Phelan-McDermid Syndrome
Keywords
SHANK3, IGF-1, Autism
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
19 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Insulin-Like Growth Factor-1 (IGF-1)
Arm Type
Experimental
Arm Description
Injection
Arm Title
Normal saline
Arm Type
Placebo Comparator
Arm Description
Injection
Intervention Type
Drug
Intervention Name(s)
Insulin-Like Growth Factor-1 (IGF-1)
Other Intervention Name(s)
Mecasermin; Increlex
Intervention Description
IGF-1 and placebo will each be administered for 3 months with a four-week washout period in between. IGF-1 will be administered for 3 months subcutaneously.
Intervention Type
Drug
Intervention Name(s)
Normal saline
Other Intervention Name(s)
Placebo
Intervention Description
Saline solution will be administered for three months subcutaneously.
Primary Outcome Measure Information:
Title
Change in Aberrant Behavior Checklist - Social Withdrawal (ABC-SW) Subscale - Study 1
Description
16 items on ABC-SW subscale, Each item is scored as 0 (never a problem), 1 (slight problem), 2 (moderately serious problem), or 3 (severe problem). Total score from 0 to 48 with higher score indicating poorer health outcomes.
Time Frame
Baseline and Week 12
Title
Change in Aberrant Behavior Checklist - Social Withdrawal (ABC-SW) Subscale Study 2
Description
16 items on ABC-SW subscale, Each item is scored as 0 (never a problem), 1 (slight problem), 2 (moderately serious problem), or 3 (severe problem). Total score from 0 to 48 with higher score indicating poorer health outcomes..
Time Frame
Baseline and Week 12
Secondary Outcome Measure Information:
Title
Change in Repetitive Behavior Scale - Study 2
Description
Repetitive Behavior Scale (RBS) - Total Score 43 items, each item scored on 4-point scale: 0-Behavior does not occur, 1-Behavior occurs and is a mild problem, 2-Behavior occurs and is a moderate problem, 3-Behavior occurs and is a severe problem. with total score from 0 (mild) to 129 (severe).
The subscales are stereotyped behaviors 6 items (subscale 0-18), self-injurious behaviors 8 items (subscale 0-24), Compulsive behaviors- 8 items (subscale 0-24), Ritualistic Behaviors 6 items (subscale from 0-18), Sameness 11 items (subscale 0-33), restricted behaviors 4 items (subscale 0-12). Total score is the sum of all items in the subscale with total score range from 0 to 129. Higher scores indicate greater symptom severity.
Time Frame
Baseline and Week 12
Title
Change in CGI-Improvement and Severity Scales; - Study 2
Description
The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.
The Clinical Global Impression - Improvement scale (CGI-I) is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. and rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.
Time Frame
Baseline and Week 12
Title
Change in Caregiver Strain Questionnaire
Description
21 question tool, about caregiver strain, where each question uses a Likert scale where 1 is "Not at all" and 5 is "Very much." The full scale ranges from 21-105, where higher scores indicate more severe strain.
Time Frame
Baseline and Week 12
Title
Change in Sensory Profile (SP) - Study 2
Description
The SP is a standardized parent-completed questionnaire that assesses sensory processing and its impact on the functioning of children ages 3-10 yr. The 125 items represent behaviors that can be interpreted as responses to sensory experiences. The parent rates the observed frequency of these behaviors on a 5-point Likert scale (ranging from 1 always to 5 never). The tool consists of 14 sections, listed below, that refer to sensory processing, modulation, and behavioral and emotional responses. Subscale scores are listed below.
Each section's raw score is compared with a threshold value to determine a category of performance: typical performance, probable difference (1 standard deviation below the mean), and definite difference (2 standard deviations below the mean). A lower raw score means a greater difference.
Time Frame
Baseline and Week 12
Title
Change in Short Sensory Profile (SSP) - Study 2
Description
The Short Sensory Profile is a caregiver report measure consisting of 38 items, each scored on a 1-point (always) to 5-point (never) Likert scale.
SSP Subscales Tactile Sensitivity (7 to 35) Taste/Smell Sensitivity (4 to 20), Movement Sensitivity (3 to 15), Under-Responsive/Seek Sensation (7 to 35) , Auditory Filtering (6 to 30), Low Energy/Weak (6 to 30), Visual/Auditory Sensitivity (5 to 25), with total scale from (38 to 190)
Lower scores indicate more sensory alterations.
Time Frame
Baseline and 12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
5 Years
Maximum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
5 to 12 years old
pathogenic deletions or mutations of the SHANK3 gene
stable medication regimens for at least three months prior to enrollment
Exclusion Criteria:
closed epiphyses
active or suspected neoplasia
intracranial hypertension
hepatic insufficiency
renal insufficiency
cardiomegaly / valvulopathy
history of allergy to IGF-1 or any component of the formulation (mecasermin)
history of extreme prematurity (<1000 grams) with associated early neo-natal complications, e.g. intra-cerebral hemorrhage, prolonged hypoxia, prolonged hypoglycemia
patients with comorbid conditions deemed too medically compromised to tolerate the risk of experimental treatment with IGF-1
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alexander Kolevzon, MD
Organizational Affiliation
Icahn School of Medicine at Mount Sinai
Official's Role
Principal Investigator
Facility Information:
Facility Name
Seaver Austin Center, Icahn School of Medicine at Mount Sinai
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
25685306
Citation
Kolevzon A, Bush L, Wang AT, Halpern D, Frank Y, Grodberg D, Rapaport R, Tavassoli T, Chaplin W, Soorya L, Buxbaum JD. A pilot controlled trial of insulin-like growth factor-1 in children with Phelan-McDermid syndrome. Mol Autism. 2014 Dec 12;5(1):54. doi: 10.1186/2040-2392-5-54. eCollection 2014. Erratum In: Mol Autism. 2015;6:31.
Results Reference
result
PubMed Identifier
35395866
Citation
Kolevzon A, Breen MS, Siper PM, Halpern D, Frank Y, Rieger H, Weismann J, Trelles MP, Lerman B, Rapaport R, Buxbaum JD. Clinical trial of insulin-like growth factor-1 in Phelan-McDermid syndrome. Mol Autism. 2022 Apr 8;13(1):17. doi: 10.1186/s13229-022-00493-7.
Results Reference
derived
Links:
URL
http://www.seaverautismcenter.org
Description
Seaver Autism Center
URL
http://www.shank3gene.org
Description
SHANK3 gene
URL
https://pmsf.org/
Description
Phelan-McDermid Syndrome Foundation
Learn more about this trial
Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)
We'll reach out to this number within 24 hrs